Contact
searchSearch
HMP Global

Pediatric Dermatology Topic Center

Featured

FDA Alerts
FDA Approves Vyjuvek for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa
08/10/2023
Jessica Garlewicz
The US Food and Drug Administration recently announced approval of VYJUVEK (beremagene geperpavec [B-VEC]) for the treatment of wounds in patients ages 6 months and older with dystrophic epidermolysis bullosa.
The US Food and Drug Administration recently announced approval of VYJUVEK (beremagene geperpavec [B-VEC]) for the treatment of wounds in patients ages 6 months and older with dystrophic epidermolysis bullosa.
The US Food and Drug...
08/10/2023
The Dermatologist
News
Patients With Pediatric Granuloma Annulare Often Present With Asthma and Atopy
01/31/2023
Lisa Kuhns, PhD, MD
Researchers aimed to perform a clinical and histopathologic evaluation of 41 pediatric GA cases in a retrospective study.
Researchers aimed to perform a clinical and histopathologic evaluation of 41 pediatric GA cases in a retrospective study.
Researchers aimed to perform a...
01/31/2023
The Dermatologist
CH
Videos
How to Teach Families About Safe Hair Care for Skin of Color
01/17/2022
Candrice Heath, MD, FAAP, FAAD
Candrice Heath, MD, discusses how to teach families about safe hair care practices for skin of color.
Candrice Heath, MD, discusses how to teach families about safe hair care practices for skin of color.
Candrice Heath, MD, discusses...
01/17/2022
The Dermatologist
CH
Videos
Integrating Skin of Color Hair Care for Young Patients
01/09/2022
Candrice Heath, MD, FAAP, FAAD
In this video, Candrice Heath, MD, shares what dermatologists should consider when treating skin of color hair in younger patients.
In this video, Candrice Heath, MD, shares what dermatologists should consider when treating skin of color hair in younger patients.
In this video, Candrice Heath,...
01/09/2022
The Dermatologist
News
Tobacco Exposure Linked to Childhood Psoriasis
12/23/2021
Lauren Mateja
A study in Pediatric Dermatology found that environmental tobacco smoke exposure at home was associated with childhood psoriasis in a Turkish population study.
A study in Pediatric Dermatology found that environmental tobacco smoke exposure at home was associated with childhood psoriasis in a Turkish population study.
A study in Pediatric Dermatology...
12/23/2021
The Dermatologist
News
Paraben Exposure Increases Atopic Dermatitis Prevalence in Young Children
12/18/2021
Lisa Kuhns, PhD, MD
High exposure to parabens in children aged 0 to 3 years increased the prevalence of atopic dermatitis (AD), according to a recent study from Japan.
High exposure to parabens in children aged 0 to 3 years increased the prevalence of atopic dermatitis (AD), according to a recent study from Japan.
High exposure to parabens in...
12/18/2021
The Dermatologist
News
Atopic Dermatitis Associated With Shorter Stature and Higher BMI in Children
12/13/2021
Lisa Kuhns, PhD, MD
Atopic dermatitis in children is associated with shorter stature, higher BMI, and lower weight in early childhood, but these associations resolve with age.
Atopic dermatitis in children is associated with shorter stature, higher BMI, and lower weight in early childhood, but these associations resolve with age.
Atopic dermatitis in children is...
12/13/2021
The Dermatologist
News
Pediatric Urticaria Resolution Associated With Elevated CD63 Levels and Thyroid Comorbidity
04/13/2021
Elevated CD63 levels and thyroid disease are associated with chronic inducible urticaria (CIndU) resolution in pediatric patients.
Elevated CD63 levels and thyroid disease are associated with chronic inducible urticaria (CIndU) resolution in pediatric patients.
Elevated CD63 levels and thyroid...
04/13/2021
The Dermatologist
News
Metabolic Syndrome and Insulin Resistance Found in Pre-Pubertal Children With Psoriasis
01/29/2021
A high prevalence of metabolic syndrome (MetS) and insulin resistance exists in pre-pubertal children with psoriasis, according to a recent publication in the European Journal of Pediatrics.
A high prevalence of metabolic syndrome (MetS) and insulin resistance exists in pre-pubertal children with psoriasis, according to a recent publication in the European Journal of Pediatrics.
A high prevalence of metabolic...
01/29/2021
The Dermatologist
News
Itch NRS Suitable for Pediatric Psoriasis Population
01/04/2021
Use of the Itch Numeric Rating Scale (NRS) in adults with psoriasis is common, but standard use in a similar pediatric population has not been established. A qualitative study supports the content validity of the Itch NRS for pediatric...
Use of the Itch Numeric Rating Scale (NRS) in adults with psoriasis is common, but standard use in a similar pediatric population has not been established. A qualitative study supports the content validity of the Itch NRS for pediatric...
Use of the Itch Numeric Rating...
01/04/2021
The Dermatologist
Q&As
Amplifying the Voice of Women in Pediatric Dermatology
12/14/2020
Lauren Mateja
Women have found an increasing presence throughout dermatology both at a general and subspecialty level, but gaps in representation remain.  Over the past decade, women have found a growing role in the...
Women have found an increasing presence throughout dermatology both at a general and subspecialty level, but gaps in representation remain.  Over the past decade, women have found a growing role in the...
...
12/14/2020
The Dermatologist

Expert Insights

CH
Videos
How to Teach Families About Safe Hair Care for Skin of Color
01/17/2022
Candrice Heath, MD, FAAP, FAAD
Candrice Heath, MD, discusses how to teach families about safe hair care practices for skin of color.
Candrice Heath, MD, discusses how to teach families about safe hair care practices for skin of color.
Candrice Heath, MD, discusses...
01/17/2022
The Dermatologist
CH
Videos
Integrating Skin of Color Hair Care for Young Patients
01/09/2022
Candrice Heath, MD, FAAP, FAAD
In this video, Candrice Heath, MD, shares what dermatologists should consider when treating skin of color hair in younger patients.
In this video, Candrice Heath, MD, shares what dermatologists should consider when treating skin of color hair in younger patients.
In this video, Candrice Heath,...
01/09/2022
The Dermatologist
Q&As
Amplifying the Voice of Women in Pediatric Dermatology
12/14/2020
Lauren Mateja
Women have found an increasing presence throughout dermatology both at a general and subspecialty level, but gaps in representation remain.  Over the past decade, women have found a growing role in the...
Women have found an increasing presence throughout dermatology both at a general and subspecialty level, but gaps in representation remain.  Over the past decade, women have found a growing role in the...
...
12/14/2020
The Dermatologist
eee
Podcasts
Dr Heath Shares Clinical Pearls for Treating Pediatric Patients
10/02/2020
Candrice Heath, MD, shared her insights on treating pediatric patients, and why it is important for all dermatologists, including those who only see adults, to learn about treating younger patients.
Candrice Heath, MD, shared her insights on treating pediatric patients, and why it is important for all dermatologists, including those who only see adults, to learn about treating younger patients.
Candrice Heath, MD, shared her...
10/02/2020
The Dermatologist
Cover Story
More to Skin Than Meets the Eye: Bullying and Childhood Skin Conditions
09/11/2020
Sasha D. Jaquez, PhD; Maria A. Leszczynska, MD
Bullying is common in childhood, and children with visible skin conditions can be highly vulnerable. Dermatologists can play a critical role into helping their pediatric patients through early screening and management.
Bullying is common in childhood, and children with visible skin conditions can be highly vulnerable. Dermatologists can play a critical role into helping their pediatric patients through early screening and management.
Bullying is common in childhood,...
09/11/2020
The Dermatologist
Feature Story
Treating Molluscum Contagiosum: Current Choices vs the Future Pipeline
02/13/2020
Without approved treatment options for molluscum contagiosum, doctors have differing opinions on how and even whether to treat. Recent interviews with dermatologists and pediatricians offer insight into the treatments that these two...
Without approved treatment options for molluscum contagiosum, doctors have differing opinions on how and even whether to treat. Recent interviews with dermatologists and pediatricians offer insight into the treatments that these two...
Without approved treatment...
02/13/2020
The Dermatologist
Cover Story
More Than Cosmetic: Reframing Hyperpigmentation as a Clinical and Psychosocial Priority
03/09/2026
Oyetewa Boluwatito Asempa, MD, FAAD; Coleen Stern, MA; Riya Gandhi, MA
Dr Oyetewa Asempa explores the clinical, psychosocial, and equity-driven imperatives reshaping how dermatologists diagnose and treat hyperpigmentation disorders in patients with skin of color.
Dr Oyetewa Asempa explores the clinical, psychosocial, and equity-driven imperatives reshaping how dermatologists diagnose and treat hyperpigmentation disorders in patients with skin of color.
Dr Oyetewa Asempa explores the...
03/09/2026
The Dermatologist
Feature Story
Biosimilars in Dermatology: What Clinicians Need to Know in 2026
03/09/2026
Omar Raheel, BA; Jade Bajic, BSc; Ryan Hirsh, BS; Steven R. Feldman, MD, PhD
Get the answers to key questions about biosimilars, including what they are, how they are regulated, and how they affect prescribing, insurance coverage, and patient care.
Get the answers to key questions about biosimilars, including what they are, how they are regulated, and how they affect prescribing, insurance coverage, and patient care.
Get the answers to key questions...
03/09/2026
The Dermatologist
Feature Story
Beyond the Gut: Recognizing and Managing Inflammatory Bowel Disease in Dermatologic Practice
03/09/2026
David Fudman, MD; Riya Gandhi, MA
Gastroenterologist Dr David Fudman examines our evolving understanding of the gut-skin axis and the pivotal role dermatologists play in identifying and comanaging the cutaneous symptoms of luminal disease.
Gastroenterologist Dr David Fudman examines our evolving understanding of the gut-skin axis and the pivotal role dermatologists play in identifying and comanaging the cutaneous symptoms of luminal disease.
Gastroenterologist Dr David...
03/09/2026
The Dermatologist
HSF-Reviewed Content
From Reactive to Proactive: Building Longitudinal Care Plans That Actually Work for Hidradenitis Suppurativa
03/09/2026
Mondana Ghias, MD, FAAD
Through a longitudinal approach, care teams can achieve greater clarity, stability, and long-term disease control.
Through a longitudinal approach, care teams can achieve greater clarity, stability, and long-term disease control.
Through a longitudinal approach,...
03/09/2026
The Dermatologist
Peter Lio
Expert Insights
Environmental Triggers of Atopic Dermatitis & Seasonal Allergies
03/05/2026
Peter Lio, MD, FAAD
In this interview, Peter Lio, MD, explores how modern environmental exposures—from pollution to lifestyle shifts—are accelerating type 2 inflammation and fueling atopic dermatitis and seasonal allergies in today’s patients.
In this interview, Peter Lio, MD, explores how modern environmental exposures—from pollution to lifestyle shifts—are accelerating type 2 inflammation and fueling atopic dermatitis and seasonal allergies in today’s patients.
In this interview, Peter Lio,...
03/05/2026
Allergy & Immunology
Dr Brett King
Videos
Expectations for JAK Inhibitor Treatment of Alopecia Areata
03/04/2026
Brett A. King, MD, PhD
Oral JAK inhibitors are appropriate for moderate or rapidly progressive alopecia areata, with regrowth often requiring 6 to 12 months and careful tapering, and failure of one agent not predicting failure of another.
Oral JAK inhibitors are appropriate for moderate or rapidly progressive alopecia areata, with regrowth often requiring 6 to 12 months and careful tapering, and failure of one agent not predicting failure of another.
Oral JAK inhibitors are...
03/04/2026
The Dermatologist
Brian Kim, MD, MTR
Videos
Type 2 Inflammation and the Biology of Itch in Prurigo Nodularis
03/02/2026
Brian Kim, MD, MTR, FAAD
Chronic itch in prurigo nodularis is increasingly understood as a neuroimmune process driven by type 2 cytokines rather than histamine alone. In this interview, Dr Kim explores how IL-4, IL-13, and IL-31 interact with sensory neurons to...
Chronic itch in prurigo nodularis is increasingly understood as a neuroimmune process driven by type 2 cytokines rather than histamine alone. In this interview, Dr Kim explores how IL-4, IL-13, and IL-31 interact with sensory neurons to...
Chronic itch in prurigo...
03/02/2026
The Dermatologist
Fabrizio Galimberti, MD
Videos
Treating Generalized Pustular Psoriasis
02/28/2026
Jessica Garlewicz
Generalized pustular psoriasis (GPP) is a rare but life-threatening condition that requires early recognition and prompt intervention.
Generalized pustular psoriasis (GPP) is a rare but life-threatening condition that requires early recognition and prompt intervention.
Generalized pustular psoriasis...
02/28/2026
The Dermatologist
Blauvelt
Videos
Oral IL-23 Therapies in Psoriasis: Addressing Undertreatment, Adherence, and Patient Preference
02/17/2026
Riya Gandhi, MA
Dr Andrew Blauvelt discusses how emerging oral IL-23 therapies may address persistent gaps in psoriasis care, including undertreatment and nonadherence.
Dr Andrew Blauvelt discusses how emerging oral IL-23 therapies may address persistent gaps in psoriasis care, including undertreatment and nonadherence.
Dr Andrew Blauvelt discusses how...
02/17/2026
The Dermatologist
Melissa Piliang
Videos
Managing Eyebrow & Eyelash Loss in Alopecia Areata: Emotional Impact & Treatment Insights
02/01/2026
Melissa Piliang, MD
In an insightful conversation with Dr Melissa Piliang, we explore how eyebrow and eyelash loss affects patients’ quality of life, advancements in treatment options, and how new clinical trials are offering hope for patients.
In an insightful conversation with Dr Melissa Piliang, we explore how eyebrow and eyelash loss affects patients’ quality of life, advancements in treatment options, and how new clinical trials are offering hope for patients.
In an insightful conversation...
02/01/2026
The Dermatologist

News and Quizzes

FDA Alerts
FDA Approves Vyjuvek for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa
08/10/2023
Jessica Garlewicz
The US Food and Drug Administration recently announced approval of VYJUVEK (beremagene geperpavec [B-VEC]) for the treatment of wounds in patients ages 6 months and older with dystrophic epidermolysis bullosa.
The US Food and Drug Administration recently announced approval of VYJUVEK (beremagene geperpavec [B-VEC]) for the treatment of wounds in patients ages 6 months and older with dystrophic epidermolysis bullosa.
The US Food and Drug...
08/10/2023
The Dermatologist
News
Patients With Pediatric Granuloma Annulare Often Present With Asthma and Atopy
01/31/2023
Lisa Kuhns, PhD, MD
Researchers aimed to perform a clinical and histopathologic evaluation of 41 pediatric GA cases in a retrospective study.
Researchers aimed to perform a clinical and histopathologic evaluation of 41 pediatric GA cases in a retrospective study.
Researchers aimed to perform a...
01/31/2023
The Dermatologist
News
Tobacco Exposure Linked to Childhood Psoriasis
12/23/2021
Lauren Mateja
A study in Pediatric Dermatology found that environmental tobacco smoke exposure at home was associated with childhood psoriasis in a Turkish population study.
A study in Pediatric Dermatology found that environmental tobacco smoke exposure at home was associated with childhood psoriasis in a Turkish population study.
A study in Pediatric Dermatology...
12/23/2021
The Dermatologist
News
Paraben Exposure Increases Atopic Dermatitis Prevalence in Young Children
12/18/2021
Lisa Kuhns, PhD, MD
High exposure to parabens in children aged 0 to 3 years increased the prevalence of atopic dermatitis (AD), according to a recent study from Japan.
High exposure to parabens in children aged 0 to 3 years increased the prevalence of atopic dermatitis (AD), according to a recent study from Japan.
High exposure to parabens in...
12/18/2021
The Dermatologist
News
Atopic Dermatitis Associated With Shorter Stature and Higher BMI in Children
12/13/2021
Lisa Kuhns, PhD, MD
Atopic dermatitis in children is associated with shorter stature, higher BMI, and lower weight in early childhood, but these associations resolve with age.
Atopic dermatitis in children is associated with shorter stature, higher BMI, and lower weight in early childhood, but these associations resolve with age.
Atopic dermatitis in children is...
12/13/2021
The Dermatologist
News
Pediatric Urticaria Resolution Associated With Elevated CD63 Levels and Thyroid Comorbidity
04/13/2021
Elevated CD63 levels and thyroid disease are associated with chronic inducible urticaria (CIndU) resolution in pediatric patients.
Elevated CD63 levels and thyroid disease are associated with chronic inducible urticaria (CIndU) resolution in pediatric patients.
Elevated CD63 levels and thyroid...
04/13/2021
The Dermatologist
psoriasis0
News
Altered Lysine Crotonylation Identified in Psoriatic Skin
03/19/2026
Jessica Garlewicz
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a...
03/19/2026
The Dermatologist
FDA Alerts
FDA Approves Icotyde (icotrokinra) for the Treatment of Moderate-To-Severe Plaque Psoriasis in Adults and Pediatric Patients
03/18/2026
Jessica Garlewicz
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug...
03/18/2026
The Dermatologist
FDA Alerts
FDA Approves Cosentyx for the Treatment of Pediatric Patients Aged 12 Years and Older With Moderate-To-Severe Hidradenitis Suppurativa
03/17/2026
Jessica Garlewicz
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug...
03/17/2026
The Dermatologist
Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist
Quiz
Rethinking Severity and JAK Inhibitor Strategy in Alopecia Areata
03/12/2026
Riya Gandhi, MA
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine...
03/12/2026
The Dermatologist
atopic dermatitis
News
Mixed Associations Between Socioeconomic Status and Pediatric Atopic Dermatitis Highlight Research Gaps
03/11/2026
Jessica Garlewicz
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to...
03/11/2026
The Dermatologist
FDA Alerts
FDA Approves Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis
03/10/2026
Jessica Garlewicz
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food...
03/10/2026
The Dermatologist
Quiz
Cytokine Hierarchy and Sustained Pruritus in PN
03/10/2026
Riya Gandhi, MA
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and...
03/10/2026
The Dermatologist
Quiz
Type 2 Inflammation as a Pathogenic Driver in Prurigo Nodularis
03/05/2026
Riya Gandhi, MA
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how...
03/05/2026
The Dermatologist
psoriasis
News
Biologic Therapy Improves Psychological Well-Being and Quality of Life in Psoriasis
03/03/2026
Jessica Garlewicz
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for...
03/03/2026
The Dermatologist
cover March 2026

Current Issue

March 2026
Volume 34
Issue 2
Current Issue
Issue Archive
The Dermatologist Newsletter

Recent News

FDA Alerts
FDA Approves Vyjuvek for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa
08/10/2023
Jessica Garlewicz
The US Food and Drug Administration recently announced approval of VYJUVEK (beremagene geperpavec [B-VEC]) for the treatment of wounds in patients ages 6 months and older with dystrophic epidermolysis bullosa.
The US Food and Drug Administration recently announced approval of VYJUVEK (beremagene geperpavec [B-VEC]) for the treatment of wounds in patients ages 6 months and older with dystrophic epidermolysis bullosa.
The US Food and Drug...
08/10/2023
The Dermatologist
News
Patients With Pediatric Granuloma Annulare Often Present With Asthma and Atopy
01/31/2023
Lisa Kuhns, PhD, MD
Researchers aimed to perform a clinical and histopathologic evaluation of 41 pediatric GA cases in a retrospective study.
Researchers aimed to perform a clinical and histopathologic evaluation of 41 pediatric GA cases in a retrospective study.
Researchers aimed to perform a...
01/31/2023
The Dermatologist
News
Tobacco Exposure Linked to Childhood Psoriasis
12/23/2021
Lauren Mateja
A study in Pediatric Dermatology found that environmental tobacco smoke exposure at home was associated with childhood psoriasis in a Turkish population study.
A study in Pediatric Dermatology found that environmental tobacco smoke exposure at home was associated with childhood psoriasis in a Turkish population study.
A study in Pediatric Dermatology...
12/23/2021
The Dermatologist
News
Paraben Exposure Increases Atopic Dermatitis Prevalence in Young Children
12/18/2021
Lisa Kuhns, PhD, MD
High exposure to parabens in children aged 0 to 3 years increased the prevalence of atopic dermatitis (AD), according to a recent study from Japan.
High exposure to parabens in children aged 0 to 3 years increased the prevalence of atopic dermatitis (AD), according to a recent study from Japan.
High exposure to parabens in...
12/18/2021
The Dermatologist
News
Atopic Dermatitis Associated With Shorter Stature and Higher BMI in Children
12/13/2021
Lisa Kuhns, PhD, MD
Atopic dermatitis in children is associated with shorter stature, higher BMI, and lower weight in early childhood, but these associations resolve with age.
Atopic dermatitis in children is associated with shorter stature, higher BMI, and lower weight in early childhood, but these associations resolve with age.
Atopic dermatitis in children is...
12/13/2021
The Dermatologist
News
Pediatric Urticaria Resolution Associated With Elevated CD63 Levels and Thyroid Comorbidity
04/13/2021
Elevated CD63 levels and thyroid disease are associated with chronic inducible urticaria (CIndU) resolution in pediatric patients.
Elevated CD63 levels and thyroid disease are associated with chronic inducible urticaria (CIndU) resolution in pediatric patients.
Elevated CD63 levels and thyroid...
04/13/2021
The Dermatologist
psoriasis0
News
Altered Lysine Crotonylation Identified in Psoriatic Skin
03/19/2026
Jessica Garlewicz
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a...
03/19/2026
The Dermatologist
FDA Alerts
FDA Approves Icotyde (icotrokinra) for the Treatment of Moderate-To-Severe Plaque Psoriasis in Adults and Pediatric Patients
03/18/2026
Jessica Garlewicz
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug...
03/18/2026
The Dermatologist
FDA Alerts
FDA Approves Cosentyx for the Treatment of Pediatric Patients Aged 12 Years and Older With Moderate-To-Severe Hidradenitis Suppurativa
03/17/2026
Jessica Garlewicz
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug...
03/17/2026
The Dermatologist
atopic dermatitis
News
Mixed Associations Between Socioeconomic Status and Pediatric Atopic Dermatitis Highlight Research Gaps
03/11/2026
Jessica Garlewicz
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to...
03/11/2026
The Dermatologist
FDA Alerts
FDA Approves Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis
03/10/2026
Jessica Garlewicz
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food...
03/10/2026
The Dermatologist
psoriasis
News
Biologic Therapy Improves Psychological Well-Being and Quality of Life in Psoriasis
03/03/2026
Jessica Garlewicz
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for...
03/03/2026
The Dermatologist
psoriasis
News
Low Prevalence but Meaningful Impact of Psychological Symptoms Seen in Well-Controlled Psoriasis
02/03/2026
Jessica Garlewicz
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms...
02/03/2026
The Dermatologist
psoriasis
News
Mathematical Modeling Study Highlights Cytokine Balance and Stem Cell Feedback in Psoriasis Control
01/22/2026
Jessica Garlewicz
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study...
01/22/2026
The Dermatologist
Cutaneous Squamous Cell Carcinoma
News
Managing Cutaneous Squamous Cell Carcinoma
01/06/2026
Jessica Garlewicz
An updated evidence-based review outlines contemporary strategies for evaluating and managing cutaneous squamous cell carcinoma.
An updated evidence-based review outlines contemporary strategies for evaluating and managing cutaneous squamous cell carcinoma.
An updated evidence-based review...
01/06/2026
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Roflumilast Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5
10/06/2025
Riya Gandhi, MA
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA...
10/06/2025
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use